CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

testosterone

· ingredient testosterone3-oxoandrosten (4) derivatives· TESTOSTERONE 16.2 mg/g; TESTOSTERONE 20.25 mg/1.25g; TESTOSTERONE 40.5 mg/2.5g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$0.45945
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per GM — the trend nobody else shows. 7 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other testosterone products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.

ProductNADAC / GMvs this
testosterone$0.61771+$0.15830
AndroGel$0.65670+$0.19720
Testosterone$0.91844+$0.45900
Testim$2.24+$1.78
testosterone$2.97+$2.51
Depo-Testosterone$5.41+$4.95
testosterone cypionate$11.19+$10.73
AZMIRO$11.19+$10.73

Medicare Part D coverage · CY2026

On 308 plan formularies · typical tier 4
Prior auth 90% · Step therapy 0% · Quantity limit 81% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.